Johnson & Johnson $JNJ Shares Sold by Stratos Wealth Advisors LLC

Key Points

• Stratos Wealth Advisors cut its Johnson & Johnson stake by 14% in Q4, selling 6,408 shares and now holding 39,499 shares valued at about $8.17 million.
• Company insiders sold roughly 30,142 shares worth $7.36 million over the last quarter — including EVP Vanessa Broadhurst and EVP Timothy Schmid — and insiders now own just 0.16% of JNJ stock.
• JNJ is trading around $240.87 with a market cap near $580 billion and a 52‑week range of $141.50–$251.71; analysts' consensus is a Moderate Buy with an average target of $236.91.

Stratos Wealth Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 14.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,499 shares of the company's stock after selling 6,408 shares during the quarter. Stratos Wealth Advisors LLC's holdings in Johnson & Johnson were worth $8,174,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. AustralianSuper Pty Ltd raised its position in shares of Johnson & Johnson by 632.0% in the third quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company's stock valued at $16,536,000 after buying an additional 77,000 shares during the last quarter. J.W. Cole Advisors Inc. increased its holdings in shares of Johnson & Johnson by 2.2% in the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company's stock valued at $24,278,000 after purchasing an additional 2,769 shares during the last quarter. Guinness Asset Management LTD increased its holdings in shares of Johnson & Johnson by 0.4% in the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company's stock valued at $251,216,000 after purchasing an additional 5,994 shares during the last quarter. Treasurer of the State of North Carolina increased its holdings in shares of Johnson & Johnson by 8.3% in the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company's stock valued at $188,638,000 after purchasing an additional 94,957 shares during the last quarter. Finally, National Pension Service increased its holdings in shares of Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company's stock valued at $913,484,000 after purchasing an additional 151,707 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 30,142 shares of company stock valued at $7,360,528. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock opened at $240.87 on Tuesday. The business has a fifty day moving average of $240.25 and a two-hundred day moving average of $213.73. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock has a market cap of $580.15 billion, a price-to-earnings ratio of 21.80, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on JNJ shares. UBS Group reaffirmed a "buy" rating on shares of Johnson & Johnson in a report on Monday, January 5th. Guggenheim raised their price objective on shares of Johnson & Johnson from $227.00 to $240.00 and gave the stock a "buy" rating in a research report on Friday, January 23rd. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an "overweight" rating in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a "hold" rating in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $236.91.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.